GoodRx Holdings, Inc. (NASDAQ:GDRX) shares are up on Wednesday as the company expands access to Novo Nordisk A/S’ (NYSE:NVO) Wegovy HD, a higher dose GLP-1 treatment available for self-pay patients at $399 per month.

• GoodRx Holdings shares are advancing steadily. What’s driving GDRX shares up?

This move comes amid a growing demand for GLP-1 treatments, which reflects GoodRx’s ongoing efforts to simplify access to medications.

GoodRx is a platform for medication savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually.

In March, the U.S. Food and Drug Administration (FDA) approved a higher-dose version of  Wegovy, marking an expansion of its treatment portfolio for adults with obesity.

Tiered Pricing Structure Offers Flexibility

Pricing scales with quantity, with a two-month supply available ...